Evidence map›Paper›PMID 35659674›Full record

ArticleTranslational oncology2022

PSMA theragnostics for metastatic castration resistant prostate cancer.

Hong Song, Kip E Guja, Andrei Iagaru

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Hong SongDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University and Hospital, 300 Pasteur Dr H2200, Stanford 94305, United States.
Kip E GujaDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University and Hospital, 300 Pasteur Dr H2200, Stanford 94305, United States.
Andrei IagaruDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University and Hospital, 300 Pasteur Dr H2200, Stanford 94305, United States. Electronic address: aiagaru@stanford.edu.
Stanford University · USStanford Health Care · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There has been tremendous growth in the development of theragnostics for personalized cancer diagnosis and treatment over the past two decades. In prostate cancer, the new generation of prostate specific membrane antigen (PSMA) small molecular inhibitor-based imaging agents achieve extraordinary tumor to background ratios and allow their therapeutic counterparts to deliver effective tumor doses while minimizing normal tissue toxicity. The PSMA targeted small molecule positron emission tomography (PET) agents

Indexed as

Prostate cancerProstate specific membrane antigenPSMATargeted radionuclide therapyTheragnosticsTheranostics

Identifiers

PMID35659674
PMCPMC9163091
OpenAlexW4281687151

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.